TY - JOUR
T1 - The CASE adherence index
T2 - A novel method for measuring adherence to antiretroviral therapy
AU - Mannheimer, S. B.
AU - Mukherjee, R.
AU - Hirschhorn, L. R.
AU - Dougherty, J.
AU - Celano, S. A.
AU - Ciccarone, D.
AU - Graham, K. K.
AU - Mantell, J. E.
AU - Mundy, L. M.
AU - Eldred, L.
AU - Botsko, Michael
AU - Finkelstein, R.
N1 - Funding Information:
Source of support: Health Resources and Services Administration, HIV AIDS Bureau, Special Projects of National Significance, Grant #6 H97 HA 00128-03 05, CFDA # 93.928.
PY - 2006/10/1
Y1 - 2006/10/1
N2 - The Center for Adherence Support Evaluation (CASE) Adherence Index, a simple composite measure of self-reported antiretroviral therapy (ART) adherence, was compared to a standard three-day self-reported adherence measure among participants in a longitudinal, prospective cross-site evaluation of 12 adherence programs throughout the United States. The CASE Adherence Index, consisting of three unique adherence questions developed for the cross-site study, along with a three-day adherence self-report were administered by interviews every three months over a one-year period. Data from the three cross-site adherence questions (individually and in combination) were compared to three -day self-report data and HIV RNA and CD4 outcomes in cross-sectional analyses. The CASE Adherence Index correlated strongly with the three-day self-reported adherence data (p <0.001) and was more strongly associated with HIV outcomes, including a 1-log decline in HIV RNA level (maximum OR=2.34; p <0.05), HIV RNA <400 copies/ml (maximum OR=2.33; p <0.05) and performed as well as the three-day self-report when predicting CD4 count status. Participants with a CASE Index score >10 achieved a 98 cell mean increase in CD4 count over 12 months, compared to a 41 cell increase for those with scores ≥10 (p <0.05). The CASE Adherence Index is an easy to administer instrument that provides an alternative method for assessing ART adherence in clinical settings.
AB - The Center for Adherence Support Evaluation (CASE) Adherence Index, a simple composite measure of self-reported antiretroviral therapy (ART) adherence, was compared to a standard three-day self-reported adherence measure among participants in a longitudinal, prospective cross-site evaluation of 12 adherence programs throughout the United States. The CASE Adherence Index, consisting of three unique adherence questions developed for the cross-site study, along with a three-day adherence self-report were administered by interviews every three months over a one-year period. Data from the three cross-site adherence questions (individually and in combination) were compared to three -day self-report data and HIV RNA and CD4 outcomes in cross-sectional analyses. The CASE Adherence Index correlated strongly with the three-day self-reported adherence data (p <0.001) and was more strongly associated with HIV outcomes, including a 1-log decline in HIV RNA level (maximum OR=2.34; p <0.05), HIV RNA <400 copies/ml (maximum OR=2.33; p <0.05) and performed as well as the three-day self-report when predicting CD4 count status. Participants with a CASE Index score >10 achieved a 98 cell mean increase in CD4 count over 12 months, compared to a 41 cell increase for those with scores ≥10 (p <0.05). The CASE Adherence Index is an easy to administer instrument that provides an alternative method for assessing ART adherence in clinical settings.
UR - http://www.scopus.com/inward/record.url?scp=33748710812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748710812&partnerID=8YFLogxK
U2 - 10.1080/09540120500465160
DO - 10.1080/09540120500465160
M3 - Article
C2 - 16971298
AN - SCOPUS:33748710812
SN - 0954-0121
VL - 18
SP - 853
EP - 861
JO - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
JF - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
IS - 7
ER -
